# US 2024/0200100 A1 · Packaging cells with targeted gene knockouts that improve retroviral vector titers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200100 A1
- Document ID: US20240200100A1
- Status: Published application
- Kind: A1
- Application number: 18/555,508
- Filed: 2022-04-19
- Published: 2024-06-20
- Earliest claimed: 2021-04-20
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Donald B. Kohn; Roger Paul Hollis; Jiaying Han
- Web page: https://patentgrep.com/patent/US20240200100A1

## CPC

- C12N 15/86: Viral vectors
- C12N 5/0686: {Kidney cells}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In various embodiments packaging cells are provided that increase provide increased titer and are useful for lentiviral production. In certain embodiments the packaging cells comprise a knockout of one or more genes selected from the group consisting of IFNAR1, ATR, OAS1, LDLR, and PKR.

## Claims

### Claim 1

A recombinant retroviral packaging cell, said packaging cell comprising:
a mammalian cell wherein one or more mammalian genes that inhibit virus production are knocked out or knocked down, said one or more mammalian genes that inhibit virus production comprise
(a) a mammalian gene that encodes a low-density lipoprotein receptor (LDLR);
(b) a mammalian gene that encodes interferon alpha and beta receptor subunit 1 (IFNAR1) or interferon alpha and beta receptor subunit 2 (IFNAR2) or a combination thereof of;
(c) one or more mammalian genes that regulates the DNA damage response pathway;
(d) one or more mammalian genes that regulates transcription; or
(e) one or more mammalian genes that regulates innate immunity; or
(f) any combination of (a)-(e) above.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The packaging cell according to claim 1, wherein said cell is modified to provide at least two packaging components for the surface or envelope of a retrovirus, wherein optionally, said packaging cell is modified to express retroviral Gag, Pol, and Env genes.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The packaging cell of claim 1, wherein
said one or more mammalian genes that regulates innate immunity comprises 2′-5′-oligoadenylate synthetase 1 (OAS1), 2′-5′-oligoadenylate synthetase 2 (OAS2), 2′-5′-oligoadenylate synthetase 3 (OAS3), or 2′-5′-oligoadenylate synthetase like (OASL), or a combination thereof;
said one or more mammalian genes that regulates the DNA damage response pathway or regulates transcription comprises the PKR gene (a gene that encodes protein kinase R); or
said one or more mammalian genes that regulates the DNA damage response pathway comprises the ATR gene (a gene that encodes serine/threonine-protein kinase ATR); or
any combination thereof.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 8)

The packaging cell of claim 8, wherein ATR is knocked down and not knocked out.

### Claim 20

(canceled)

### Claim 21 (depends on 8)

The packaging cell according to claim 8, wherein said one or more mammalian genes that are knocked out or knocked down comprise a member of the OAS gene family, PKR, LDLR or any combination thereof, optionally, wherein said one or more mammalian genes that are knocked out or knocked down comprise one or more genes selected from the group consisting of OAS1, LDLR, and PKR.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The packaging cell of claim 21, wherein said one or more mammalian genes that are knocked out or knocked down comprise OAS1.

### Claim 24 (depends on 21)

The packaging cell according to claim 21, wherein said one or more mammalian genes that are knocked out or knocked down comprise LDLR.

### Claim 25 (depends on 21)

The packaging cell according to claim 21, wherein said one or more mammalian genes that are knocked out or knocked down comprise PKR.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 1)

The packaging cell according to claim 1, wherein said cell is further modified to express or to overexpress a transcription elongation factor.

### Claim 33 (depends on 32)

The packaging cell of claim 32, wherein said transcription elongation factor is selected from SPT4 and/or SPT5.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The packaging cell according to claim 33, wherein an expression cassette that expresses elongation factors SPT4 and/or SPT5 is episomal in said packaging cell or is integrated into the genome of said packaging cell.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The packaging cell according to claim 1, wherein said mammalian cell is selected from the group consisting of HEK293, HEK293T, TE671, HT1080, 3T3, K562, 3T3, U937, and H9.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

The packaging cell according to claim 1, wherein said cell, when transfected with a defective recombinant retroviral genome, produces complete virion at a higher titer and/or infectivity than the same cell without said one or more mammalian genes knocked out and without transcription elongation factors overexpressed.

### Claim 42 (depends on 41)

The packaging cell of claim 41, wherein said packaging cell increases lentiviral vector titer, increases titer for complex lentiviral vectors, or increases titer for lentiviral vectors in reverse orientation.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 1)

The packaging cell according to claim 1, wherein said cell is further transfected with a defective, recombinant retroviral genome containing a nucleotide sequence of interest, wherein optionally, said nucleotide sequence of interest comprises a gene or cDNA selected from the group consisting of βAS3, FOXP3, WAS, RAG1, CAR (chimeric antigen receptor), and TCR (T-cell receptor).

### Claim 46 (depends on 45)

The packaging cell of claim 45, wherein said defective, recombinant retroviral genome comprises a lentiviral (LV) genome, wherein optionally said LV genome comprises an HIV LV genome or comprises an expression cassette in reverse orientation or a combination thereof.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50 (depends on 46)

The packaging cell of claim 46, wherein said LV genome comprises Lenti/βAS3-FB.

### Claim 51 (depends on 1)

A method of producing a retrovirus vector, said method comprising:
transfecting a packaging cell according to claim 1 with a defective, recombinant retroviral genome containing a nucleotide sequence of interest; and culturing said transfected packaging cell
wherein said defective, recombinant retroviral genome is packaged within a viral capsid within said cultured cell to produce a virion; and
recovering and isolating said virion.

### Claim 52 (depends on 51)

The method of claim 51, wherein said defective, recombinant retroviral genome is selected from a lentiviral (LV) genome, an HIV LV genome, and a VL genome in reverse orientation.

### Claim 53

(canceled)

### Claim 54 (depends on 51)

The method according to claim 51, wherein said nucleotide sequence of interest comprises a gene or cDNA selected from the group consisting of βAS3, FOXP3, WAS, RAG1, CAR, and TCR.
